FILING ANALYSIS · THURSDAY, NOVEMBER 12
Altimmune, Inc. ALT — 8-K: Results of Operations and Financial Condition
neutral
The company reported a cash position of $480 million and provided updates on its clinical development programs, including the global PERFORMA Phase 3 trial in MASH and the End-of-Phase 2 meeting with the FDA for the AUD program, but did not disclose any significant quantified surprises.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →